Key Points Bristol Myers Squibb just announced an important partnership with Microsoft that involves AI. Intuitive Surgical has integrated AI real-time processing into its surgical robots, but that could be just the start. 10 stocks we like better than Bristol Myers Squibb › Artificial intelligence chip giant Nvidia has grown to be the largest component of the S&P 500, as Wall Street jumps on the AI bandwagon. There's no question that AI is going to be a world-changing technology. However, it isn't ...

Core Viewpoint - Nexalin Technology, Inc. has received a notification from NASDAQ regarding non-compliance with the minimum bid price requirement for continued listing, specifically under NASDAQ Listing Rule 5550(a)(2) [1][2] Group 1: Compliance Notification - The company is not in compliance with the minimum bid price requirement of US$1.00 per share, as its shares have not met this threshold for 30 consecutive business days [2] - The company has been given 180 calendar days, until July 20, 2026, to regain compliance by achieving a closing bid price of at least US$1.00 for a minimum of 10 consecutive trading days [3] - The receipt of the notification does not immediately affect the trading of the company's shares, which will continue to trade on NASDAQ under the ticker "NXL" [4] Group 2: Company Actions and Future Plans - The company intends to monitor its bid price continuously and is considering various measures to improve its financial position and operational results [4] - The company is not currently considering a reverse stock split as a means to address the bid price deficiency [4] Group 3: Company Overview - Nexalin Technology, Inc. specializes in developing non-invasive neurostimulation products aimed at addressing mental health issues [5] - The company's devices are designed to provide relief for mental health disorders using bioelectronic medical technology, with a focus on deep brain structures [5] - The Nexalin Gen-2 15 milliamp neurostimulation device has received approval in multiple countries, including China, Brazil, Oman, and Israel [5]

Core Insights - Intuitive Surgical reported strong fourth-quarter earnings and revenue, surpassing analyst expectations, driven by growth in da Vinci and Ion procedures [1][2] Financial Performance - Adjusted earnings per share reached $2.53, exceeding the consensus estimate of $2.26 [1] - Revenue increased to $2.87 billion, surpassing expectations of $2.75 billion, marking a 19% rise from $2.41 billion in the same quarter last year [1] Procedure Growth - Da Vinci procedures grew by 17%, while Ion procedures saw a significant increase of 44% during the quarter [2] - The company placed 532 da Vinci systems in the quarter, up from 493 a year earlier, expanding the installed base to 11,106 systems, a 12% year-over-year increase [2] Revenue Breakdown - Revenue from instruments and accessories rose 17% to $1.66 billion [2] - Systems revenue increased to $786 million from $655 million in the prior-year quarter [2] Future Outlook - The company forecasts worldwide da Vinci procedure growth of approximately 13% to 15% in 2026, a decrease from 18% growth projected for 2025 [3] - Intuitive Surgical anticipates a non-GAAP gross profit margin of 67% to 68% of revenue, factoring in an estimated 1.2 percentage point impact from tariffs [3]

Core Viewpoint - Nuwellis, Inc. has appointed Katharyn Field and Mika Grasso to its board of directors, effective January 21, 2026, while three members resigned from the board, with no disagreements reported [1][4][5]. Group 1: Board Appointments - Katharyn Field is the CEO of ISpecimen Inc. and has held various leadership roles in other companies, including Halo Collective and Marimed Inc. She holds an MBA from Columbia Business School and a BA from Stanford University [2]. - Mika Grasso is an Investment Manager at a private family office with prior experience at Zions Capital Markets, Paulson Investment Company, Goldman Sachs, and Power Systems Management. He holds an MS in Finance and a BS in Business Administration from the University of Colorado Boulder [3]. Group 2: Board Resignations - Dave McDonald, Mike McCormick, and Dr. Maria Costanzo resigned from the board effective January 21, 2026, with the company confirming that these resignations were not due to any disagreements regarding operations or policies [4][5]. Group 3: Company Overview - Nuwellis, Inc. is a medical technology company focused on precision fluid management technologies for cardiorenal care, developing solutions for both acute and chronic care settings [6]. - The company's portfolio includes technologies addressing complex cardiorenal conditions, emphasizing safety, precision, and scalability [6].

As filed with the Securities and Exchange Commission on January 23, 2026. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MiniMed Group, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 33-3985981 (I.R.S. Employer Identification Number) 18000 Devonshire St. N ...

Core Viewpoint - Hagens Berman is investigating Zimmer Biomet Holdings, Inc. due to concerns over the company's previously stated "high confidence" in its 2025 revenue targets following significant operational disruptions and revenue misses in emerging markets [1][4]. Group 1: Investigation Details - The investigation focuses on whether Zimmer Biomet's senior management misled investors about the stability of its international business, particularly after assurances of strong growth in August 2025 [2][4]. - Following the company's November 5, 2025 disclosure of distributor order cancellations in emerging markets and a revenue miss in Latin America, Zimmer Biomet's stock fell by 15%, significantly impacting its market value [2][6]. Group 2: Management Statements and Market Reaction - In August 2025, management expressed "very high" confidence in achieving a year-over-year organic revenue growth forecast of 3.5% to 4.5%, which contributed to a 7% increase in share price on that day [6]. - The November 5 earnings call revealed that the actual year-over-year organic revenue growth was only 5%, leading to a reduction in the growth forecast to 4% and acknowledgment of emerging markets as a headwind [6]. Group 3: Leadership Changes and Future Guidance - Zimmer Biomet announced leadership and governance changes in response to the challenges faced in international markets throughout 2025 [6]. - CEO Ivan Tornos stated the need for more measured external commentary following the scrutiny from analysts, indicating a shift in the company's communication strategy [6].

Key Takeaways ISRG posted Q4 EPS of $2.53 and revenues of $2.87B, beating estimates and lifting the stock 2.4% after hours.ISRG saw 19.1% revenue growth from higher da Vinci placements and rising global procedure volume.ISRG's gross margin fell 210 bps to 67.6% as operating and R&D expenses rose year over year.Intuitive Surgical (ISRG) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, which beat the Zacks Consensus Estimate of $2.25 by 12.4%. The bottom line improved 14.5% year over y ...

Core Insights - CVRx, Inc. has initiated the BENEFIT-HF clinical trial, a significant randomized study aimed at evaluating the impact of Barostim in a larger heart failure population [1][3] - Barostim is an implantable device that enhances baroreflex signaling to improve heart failure symptoms and has been commercially available since FDA approval in 2019 [2] - The BENEFIT-HF trial is expected to be one of the largest therapeutic cardiac device trials, randomizing 2,500 patients with a primary endpoint focused on all-cause mortality and heart failure decompensation events [3] Company Developments - If successful, the BENEFIT-HF trial could potentially triple the indicated patient population for Barostim, broadening access to this heart failure management approach [4] - Analyst commentary suggests that the trial's success could significantly increase the company's total addressable market (TAM) and attract more attention within the cardiology community [5] - The trial's design includes CMS coverage, which is seen as a key milestone that could unlock additional revenue potential, with an estimated $50 million in top-line revenue from Barostim therapy for approximately 1,650 patients [5] Market Reaction - Following the announcement, CVRx shares experienced a notable increase of 15.93%, reaching $7.60 [6]

Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock about a class action lawsuit with a lead plaintiff deadline of February 9, 2026 [1]. Group 1: Class Action Details - Investors who purchased Integer common stock between July 25, 2024, and October 22, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - Investors wishing to serve as lead plaintiff must file a motion with the Court by February 9, 2026 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4]. Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is claimed that Integer overstated its visibility into customer demand and mischaracterized its EP devices as long-term growth drivers for its cardio and vascular segment [5]. - The lawsuit asserts that the positive statements made by the defendants lacked a reasonable basis, leading to investor damages when the true details were revealed [5].

Financial Performance - Intuitive Surgical reported revenue of $2.87 billion for the fourth quarter, exceeding analyst estimates of $2.75 billion [1] - The company reported adjusted earnings of $2.53 per share, surpassing analyst expectations of $2.26 per share [1] Future Expectations - Intuitive Surgical anticipates a 13% to 15% increase in worldwide da Vinci procedures for full-year 2026, a decrease from the 18% growth expected in 2025 [2] - The company expects gross profit margin to be between 67% and 68% of revenue in 2026, slightly down from 67.6% in 2025 [2] Stock Performance and Analyst Ratings - Following the earnings announcement, Intuitive Surgical shares increased by 0.2%, trading at $526.86 [2] - Bernstein analyst Lee Hambright maintained an Outperform rating and raised the price target from $740 to $750 [3] - Evercore ISI Group analyst Vijay Kumar maintained an In-Line rating and lowered the price target from $580 to $550 [3]